EVEREST MED(01952.HK)

Event Tracking

Dec31

Chairman Wu Yifang of CanSino Biologics Purchased 30,000 Shares

09:07

Dec30

CanSino Biologics Shares Plunge Over 20% After Generic Drug Approval

13:44

Dec17

CloverDX Receives FDA Approval and License from Lib Therapeutics

06:23

Dec15

Everbright Neon Announces 2030 Development Strategy

06:21

Dec14

Top Directors and Major Shareholders of CanSino Biologics Increase Their Shares

23:14

Dec11

Everbright BioTech Signs Commercialization and Licensing Agreement with Haisen Biopharma

09:02

Schedules & Filings

Schedules

Filings

Aug28

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 244.15 M, Net Income -136.7 M, EPS -0.4201

Mar25

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 215.52 M, Net Income -217.54 M, EPS -0.6706

Aug27

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 161.99 M, Net Income -339.77 M, EPS -1.0593

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change